In the BioHarmony Drug Report Database
Viloxazine
Qelbree (viloxazine) is a small molecule pharmaceutical. Viloxazine was first approved as Qelbree on 2021-04-02. It is used to treat depression in the USA. Qelbree’s patent is valid until 2033-02-07 (FDA).
Trade Name
|
Qelbree |
|---|---|
Common Name
|
viloxazine |
ChEMBL ID
|
CHEMBL306700 |
Indication
|
depression |
Drug Class
|
Antidepressant; Norepinephrine reuptake inhibitor |
Image (chem structure or protein)